Ionis Pharmaceuticals, Inc.
MODULATORS OF COMPLEMENT FACTOR B
Last updated:
Abstract:
The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with dysregulation of the complement alternative pathway by administering a Complement Factor B (CFB) specific inhibitor to a subject.
Status:
Application
Type:
Utility
Filling date:
2 Sep 2021
Issue date:
4 Aug 2022